Biomerica, Inc. announced compelling real-world results demonstrating the effectiveness of its inFoods IBS product, alongside the launch of a proprietary real-time patient feedback system. Initial analysis from over 360 patients in the real-world study revealed an average 49% reduction in abdominal discomfort, a 48% reduction in bloating, and a 46% reduction in the impact on overall well-being. These outcomes align with, and in some cases exceed, results from prior randomized clinical trials.
The ongoing study tracks symptom reduction from a two-week baseline through an eight-week intervention, during which patients eliminate specific trigger foods identified by the inFoods IBS diagnostic system. CEO Zack Irani stated that the real-time symptom tracking platform provides physicians with clinical insight throughout treatment, enabling a personalized and dynamic approach to care. This HIPAA-compliant platform gives clinicians visibility into patient-reported outcomes such as abdominal discomfort, bloating, and overall well-being.
IBS affects an estimated 10% to 15% of adults in the U.S., leading to decreased quality of life and reliance on medications with adverse side effects. The inFoods IBS diagnostic-guided therapy offers a novel, affordable, and personalized solution that identifies individual food triggers, enabling patients and providers to target dietary changes to reduce symptoms without pharmaceuticals. The real-world findings build on peer-reviewed results published in *Gastroenterology*.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.